Catch up with experts on the latest evidence related to HIV prevention, rapid-start antiretroviral (ART) therapy, and HCV screening and treatment for people who inject drugs—the population at highest risk of transmission. These expert interviews will provide the epidemiologic trends that underlie the imperative for HIV preexposure prophylaxis (PrEP), present HIV treatment as prevention (TasP), and emphasize the feasibility, efficacy, and ease of treating HCV-infected PWID.